INDP Earnings Date: Nov 17, 2026 (Estimated) — Indaptus Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is INDP's next earnings date?
Indaptus Therapeutics, Inc. (INDP) is expected to report Q3 2026 earnings on Tuesday, November 17, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.46.
How did INDP do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Indaptus Therapeutics, Inc. posted EPS of -$0.02 versus the -$0.02 estimate, a miss of 98.7%. Revenue was $0. The stock's 1-day post-earnings move was +3.9%.
How much does INDP stock move after earnings?
INDP beat EPS estimates in 5 of its last 7 reported quarters. Over the last 8 reports the stock moved an average of 5.4% (up or down) in the day after earnings.
About Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.02 | -0.02 | +98.73% | $0 | ❌ Miss | +3.92% | -7.84% | +171.57% |
| 2026-05-15 | Q1 2026 | -1.87 | -0.23 | +87.70% | $0 | ✅ Beat | -9.14% | -39.43% | +110.86% |
| 2026-03-17 | Q4 2025 | -1.87 | -3.10 | -65.78% | $0 | ❌ Miss | +12.00% | -1.14% | +54.86% |
| 2025-11-12 | Q3 2025 | -4.17 | -2.98 | +28.54% | $0 | ✅ Beat | +6.25% | -15.07% | -5.51% |
| 2025-08-13 | Q2 2025 | — | -9.09 | — | $0 | — | +2.43% | -9.89% | -65.66% |
| 2025-03-13 | Q4 2024 | -0.41 | -0.38 | +7.32% | $0 | ✅ Beat | -3.95% | -8.29% | -42.86% |
| 2024-11-12 | Q3 2024 | -0.42 | -0.32 | +23.81% | $0 | ✅ Beat | -4.96% | -9.09% | -19.01% |
| 2024-08-12 | Q2 2024 | -0.54 | -0.47 | +12.96% | $0 | ✅ Beat | +0.59% | -2.94% | -14.71% |
Showing last 8 quarters.